Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

UK: A systematic review and meta-analysis of randomized trials have highlighted the significant benefits of long-acting ...

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...